Ratings Acarix AB Deutsche Boerse AG

Equities

Market Closed - Deutsche Boerse AG Other stock markets 01:11:05 29/06/2024 am IST			5-day change	1st Jan Change
0.0321 ^EUR	+3.22%		+44.59%	+111.18%

11/06	Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study	CI
27/05	Acarix AB Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ACARIX AB	+111.18%	35.31M		-
SARTORIUS AG	-34.27%	14.56B		A
QUIDELORTHO CORPORATION	-54.93%	2.25B		C+
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+15.49%	1.84B		-
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-14.07%	1.46B		-
BIOTAGE AB	+21.99%	1.21B		B+
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-35.50%	804M		-
REVENIO GROUP OYJ	+1.25%	790M		-
CONTEC MEDICAL SYSTEMS CO.,LTD	-36.65%	734M	-	C-
VAREX IMAGING CORPORATION	-28.15%	597M		B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality